Industry: Healthcare
Published Date: October-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 312
Report ID: PMRREP12142
The global single-use bioprocess systems market recorded a CAGR of 11.9% in the last six years from 2015 to 2021. Worldwide revenue from single-use bioprocess systems was US$ 5.8 Bn in 2022, with the market forecasted to surge ahead at a CAGR of 14.4% to reach a valuation of US$ 22.2 Bn by the end of 2032.
According to this study by Persistence Market Research, overall, single-use bioprocess systems accounted for approximately 26.5% revenue share of the global bioprocess technology market in 2021.
Many end users view single-use systems (SUS) as an economically viable strategy to attain the highest level of productivity and process efficiency. SUS equipment is therefore extensively used throughout the biomanufacturing phase, especially in the production of pre-commercial biopharmaceuticals. Opportunities have been generated for the industry's product providers as a result.
One of the key factors driving the market for single-use bioprocess systems is that there are several vendors in the market who are offering sustainable disposables for the production of biopharmaceuticals and other commercial purposes. Reusable stainless steel bioreactors, which are used in conventional bioprocessing systems, have several drawbacks.
The primary driver anticipated to propel market growth is the introduction of single-use bioprocess systems that come with benefits such as less cleaning and sterilization requirements as well as possible cost reductions when compared to conventional stainless steel mixers.
Additionally, the development of automation in the bioprocessing sector has emerged as another major trend drastically increasing the efficiency of biomanufacturing. By enabling prediction and process parameters, the adoption of analytical models based on big data and machine learning is projected to improve product yields.
Moreover, rising amount of investments in single-use bioprocess systems for research and development to create sustainable solutions will further boost market growth over the next ten years.
|
Single-Use Bioprocess Systems Market Size (2022) |
US$ 5.8 Bn |
|
Projected Market Value (2032) |
US$ 22.2 Bn |
|
Global Market Growth Rate (2022-2032) |
14.4% CAGR |
|
Market Share of Top 5 Countries |
52% |
“Technological Adoption – Transforming Single-use Bioprocessing Systems Sector”
With ongoing technological upgradation and high investments by companies to make unique single-use bioprocess systems, the focus has shifted from conventional steel bioreactors to disposable single-use bioreactors that are easier and cheaper to use. Furthermore, they provide high energy efficiency and reduce the chances of cross-contamination. For instance, companies such as ThermoFisher Scientific, Eppendorf AG, Merk KGaA, and Danaher Corporation, are developing single-use bioprocessing systems and components.
The introduction of new technologies is expected to result in higher adoption rates, which will, in turn, drive market growth during the forecast period. Manufacturers are also investing a lot of time in research and development for the production of single-use bags as they are easily disposable and provide efficient temperature resistance, strength of usage, and are also quite durable. The successful launch of disposable bags of various sizes will help market leads expand their businesses with a larger product portfolio and capture a share in untapped markets.
Furthermore, with increased demand for disposable sensors and probes in the biopharmaceutical industry, new market entrants are also trying to expand their businesses by offering a wide range of products.
“Increasing Cost of Consumables and Rising Industrial Pollution”
The single-use bioprocess systems market's rising consumable product costs are anticipated to somewhat hinder market expansion. Over the coming years, the market is anticipated to be hampered by the industry's contribution to the impact of industrial pollution on the planet.
In actuality, just a small portion of the world's total plastic consumption is produced by businesses using single-use bioprocessing. However, low and mid-sized market participants' unwillingness to invest in environment-friendly product development for the biopharmaceutical industry is causing industrial pollution, which is expected to somewhat impede market growth in the years ahead.
Why is the U.S. a Lucrative Market for Single-Use Bioprocess Systems?
“Increasing R&D Funding for Innovative Single-Use Bioprocess Systems”
The U.S. accounted for 85% share of the North American single-use bioprocess systems market in 2021 and is expected to hold on to this huge share through 2032.
Expansion of biopharmaceutical R&D and the availability of major biopharmaceutical manufacturing facilities in the U.S. have been important factors in the country's supremacy. Additionally, the North American region is home to a large number of contract manufacturing businesses that use disposables in their daily operations.
Investments in this market have increased as a result of this trend. For instance:
How is the Single-Use Bioprocess Systems Market Shaping Up in China?
“Growing Biopharmaceutical Industry Raising Demand for Single-Use Bioprocess Systems Services”
China held 45.8% share of the East Asia single-use bioprocess systems market in 2021. With the expanding biopharmaceutical manufacturing sector in China, the country has become a strong market for single-use technology.
The Chinese bioprocessing sector has traditionally been seen as a conservative and cautious industry when it comes to implementing new technologies; however, recently, many of the facilities that are expanding are planning to incorporate some of the most cutting-edge technologies, such as contemporary single-use technologies (SUT) and modular components.
A majority of Monoclonal Antibody (mAb) developers in China are developing biosimilar/bio better mAbs against several known targets. Hence, lately, there has been a huge adoption of single-use bioprocess systems.
For instance:
Why is Germany an Established Player in the Market for Single-Use Bioprocess Systems?
“Expansion of Companies to Meet Demand for Complex Antibodies”
Germany held the largest market share of 26.4% of the European single-use bioprocess systems market in 2021.
With many companies expanding their production plants in Germany to meet the demand for complex antibody production and commercial biomanufacturing, the demand for single-use bio-processors is very high.
For instance, disposable single-use bioreactors greatly increase flexibility since they enable quicker ramp-up of capacity and decrease the burden for preparation.
Which Component Majorly Drives Market Growth?
“High Demand for Single-Use Bioreactors across Regions”
Under the component segment, bioreactors held 43.9% share of the global market in 2021.
Factors such as the growing number of biopharmaceutical companies and CMOs in developed regions (North America and Europe) and the growing demand for the development and manufacturing of biologics across all regions are increasing the usage of single-use bioreactors owing to their added advantages over conventional bioreactors, thus accelerating segment growth.
Which Application of Single-Use Bioprocess Systems is Most Prominent?
“Increased Demand for Drug Discovery and Pharmaceutical Products”
GMP and commercial production held the largest market share of 71.4% in 2021.
Because of the high demand for drug discovery and the commercial use of pharmaceuticals, monoclonal antibodies for laboratory usage, and cell culture, the GMP and commercial production segment is leading and will continue to hold this position throughout the forecast period.
Which End User Accounts for Greater Adoption of Single-Use Bioprocess Systems?
“Rapidly Growing Number of Biopharmaceutical Companies”
Biopharmaceutical companies accounted for a larger share of 52.1% in 2021.
Biopharmaceutical companies use single-use bioprocess systems to cater to the rising demand for biologics production in a safe environment and cost-effective way. Numerous biopharmaceutical companies have started investing in extending their manufacturing capacity through the installation of new disposable equipment to keep up with shifting client demands for vaccine manufacturing and related bioprocessing services.
The COVID-19 pandemic also increased the flow of investments into the bioprocessing sector, which is pushing the demand for single-use bioprocess systems. As such, the demand for single-use bioprocess systems in biopharmaceutical companies will continue to rise.
To strengthen their market presence and expand their product lines in the global market, leading manufacturers are focussing on various market strategies such as mergers and acquisitions, expansion of their production facilities, and collaborations with various other companies to boost their sales of single-use bioprocess systems.
For instance:
|
Attribute |
Details |
|
Forecast Period |
2022-2032 |
|
Historical Data Available for |
2015-2021 |
|
Market Analysis |
USD Billion for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
By Component:
By Application:
By End User:
By Region:
To know more about delivery timeline for this report Contact Sales
The global single-use bioprocess systems market was valued at around US$ 5 Bn in 2021.
Sales of single-use bioprocess systems are set to witness a high CAGR of 14.4% and reach US$ 22.2 Bn by 2032.
Demand for single-use bioprocess systems increased at 11.9% CAGR from 2012 to 2021.
The U.S., China, Germany, Japan, and India account for the most demand for single-use bioprocess systems, currently holding 52% market share.
The U.S. accounts for around 85% share of the North American market.
China accounts for 45.8% share of the East Asia single-use bioprocess systems market.
Thermo Fisher Scientific Inc., Sartorius Stedim Biotech, and Danaher Corporation are the top three producers of single-use bioprocess systems.
Japan held a share of 40.5% of the East Asian market in 2021.
